Evidence map›Paper›PMID 25123642›Full record

ArticleProtein expression and purification2014

Efficient production and purification of recombinant human interleukin-12 (IL-12) overexpressed in mammalian cells without affinity tag.

Srinivas Jayanthi, Bhanu prasanth Koppolu, Sean G Smith, Rashmi Jalah, Jenifer Bear, Margherita Rosati, George N Pavlakis, Barbara K Felber, David A Zaharoff, Thallapuranam Krishnaswamy Suresh Kumar

Open access · greenAbstract read
In one paragraph

Article in Protein expression and purification, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Srinivas JayanthiDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, USA.
Bhanu prasanth KoppoluDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA.
Sean G SmithDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA.
Rashmi JalahHuman Retrovirus Pathogenesis Section, Vaccine Branch-National Cancer Institute, Frederick, MD 21702-1201, USA.
Jenifer BearHuman Retrovirus Pathogenesis Section, Vaccine Branch-National Cancer Institute, Frederick, MD 21702-1201, USA.
Margherita RosatiHuman Retrovirus Section, Vaccine Branch-National Cancer Institute, Frederick, MD 21702-1201, USA.
George N PavlakisHuman Retrovirus Section, Vaccine Branch-National Cancer Institute, Frederick, MD 21702-1201, USA.
Barbara K FelberHuman Retrovirus Pathogenesis Section, Vaccine Branch-National Cancer Institute, Frederick, MD 21702-1201, USA.
David A ZaharoffDepartment of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA. Electronic address: zaharoff@uark.edu.
Thallapuranam Krishnaswamy Suresh KumarDepartment of Chemistry and Biochemistry, University of Arkansas, Fayetteville, AR 72701, USA. Electronic address: sthalla@uark.edu.
National Cancer Institute · USUniversity of Arkansas at Fayetteville · US

Funding

Structure based drug discoveryP20RR015569 · NCRR · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI SAKON, JOSHUA · 2000 to 2009
$21.4M
Posttranscriptional control of gene expressionZIABC010334 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FELBER, BARBARA K · 2009 to 2025
$15.1M
Center for Protein Structure and FunctionP30GM103450 · NIGMS · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI MILLETT, FRANCIS S · 2012 to 2014
$3.2M
Biopolymer-based strategies for local delivery of cytokine therapeuticsR01CA172631 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI ZAHAROFF, DAVID · 2014 to 2018
$1.5M
Chitosan-based Delivery and Immunopotentiation of Cancer VaccinesK22CA131567 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI ZAHAROFF, DAVID · 2010 to 2012
$505k
Intravesical Chitosan/IL-12 Immunotherapy for Bladder CarcinomaR15CA176648 · NCI · UNIVERSITY OF ARKANSAS AT FAYETTEVILLE · PI ZAHAROFF, DAVID · 2014 to 2014
$417k
Intramural NIH HHSNCI NIH HHS K22 CA131567NCI NIH HHS R01 CA172631NCI NIH HHS R15 CA176648NCRR NIH HHS 1 P20 RR15569NCRR NIH HHS P20 RR015569NIGMS NIH HHS P30 GM103450
6 · The paper itself

Abstract

Interleukin-12 is a heterodimeric, pro-inflammatory cytokine that is a key driver of cell-mediated immunity. Clinical interest in IL-12 is significant due to its potent anti-tumor activity and efficacy in controlling certain infectious diseases such as Leishmaniasis and Listeria infection. For clinical applications, the ease of production and purification of IL-12 and the associated cost continues to be a consideration. In this context, we report a simple and effective heparin-affinity based purification of recombinant human IL-12 (hIL-12) from the serum-free supernatants of stable IL-12-transduced HEK293 cells. Fractionation of culture supernatants on heparin Sepharose columns revealed that hIL-12 elutes as a single peak in 500 mM NaCl. Coomassie staining and Western blot analysis showed that hIL-12 eluted in 500 mM NaCl is homogeneous. Purity of hIL-12 was ascertained by RP-HPLC and ESI-MS analysis, and found to be ∼98%. Western blot analysis, using monoclonal antibodies, demonstrated that the crucial inter-subunit disulfide bond linking the p35 and p40 subunits is intact in the purified hIL-12. Results of far UV circular dichroism, steady-state tryptophan fluorescence, and differential scanning calorimetry experiments suggest that purified hIL-12 is in its stable native conformation. Enzyme linked immunosorbent assays (ELISAs) and bioactivity studies demonstrate that hIL-12 is obtained in high yields (0.31±0.05 mg/mL of the culture medium) and is also fully bioactive. Isothermal titration calorimetry data show that IL-12 exhibits a moderate binding affinity (Kd(app)=69±1 μM) to heparin. The purification method described in this study is expected to provide greater impetus for research on the role of heparin in the regulation of the function of IL-12. In addition, the results of this study provide an avenue to obtain high amounts of IL-12 required for structural studies which are aimed at the development of novel IL-12-based therapeutics.

Indexed as

Amino Acid SequenceBinding SitesBlotting, WesternChromatography, AffinityCloning, MolecularElectrophoresis, Polyacrylamide GelHEK293 CellsHeparinHumansInterleukin-12Models, MolecularMolecular Sequence DataProtein ConformationRecombinant ProteinsUp-RegulationHeparinInterleukin-12Recombinant ProteinsBioactivityCytokineHEK293Heparin SepharoseInterleukin-12Purification

Identifiers

PMID25123642
PMCPMC4164965
OpenAlexW2047160180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.